Beijing, Shanghai, Boston, September 27, 2024 – Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has received payment of RMB 172 million from Shanghai Allist Pharmaceuticals Co., Ltd (688578.SH), including upfront payment of RMB 150 million, as well as RMB 22.79 million in research and development expense compensation and other payments.

This payment is subject to the cooperation agreement signed between Jacobio and Allist on August 30, 2024. According to the terms of the agreement, Jacobio granted the China rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Allist.

About Jacobio
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.